149 related articles for article (PubMed ID: 17708574)
1. The timing of rhDNase in relation to airway clearance therapy-unplugged.
Tannenbaum EL; Ranganathan S
Pediatr Pulmonol; 2007 Dec; 42(12):1235; author reply 1236-7. PubMed ID: 17708574
[No Abstract] [Full Text] [Related]
2. RhDNase before airway clearance therapy improves airway patency in children with CF.
van der Giessen LJ; de Jongste JC; Gosselink R; Hop WC; Tiddens HA
Pediatr Pulmonol; 2007 Jul; 42(7):624-30. PubMed ID: 17534979
[TBL] [Abstract][Full Text] [Related]
3. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
4. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
Wilson CJ; Robbins LJ; Murphy JM; Chang AB
Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
[TBL] [Abstract][Full Text] [Related]
5. [Inhaled therapies for cystic fibrosis].
Lahzami S; Nicod LP
Rev Med Suisse; 2011 Nov; 7(318):2285-8. PubMed ID: 22400363
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.
Suri R; Wallis C; Bush A; Thompson S; Normand C; Flather M; Grieve R; Metcalfe C; Lees B
Health Technol Assess; 2002; 6(34):iii, 1-60. PubMed ID: 12583821
[No Abstract] [Full Text] [Related]
7. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
8. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis.
Geller D; Thipphawong J; Otulana B; Caplan D; Ericson D; Milgram L; Okikawa J; Quan J; Bowman CM
J Aerosol Med; 2003; 16(2):175-82. PubMed ID: 12823911
[TBL] [Abstract][Full Text] [Related]
9. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.
Suri R; Metcalfe C; Wallis C; Bush A
Respir Med; 2007 Feb; 101(2):254-60. PubMed ID: 16806875
[TBL] [Abstract][Full Text] [Related]
10. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial.
Bishop JR; Erskine OJ; Middleton PG
J Physiother; 2011; 57(4):223-9. PubMed ID: 22093120
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?
van der Giessen LJ; Gosselink R; Hop WC; Tiddens HA
Eur Respir J; 2007 Oct; 30(4):763-8. PubMed ID: 17596273
[TBL] [Abstract][Full Text] [Related]
12. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of two aerosol delivery systems for rhDNase.
Shah PL; Scott SF; Geddes DM; Conway S; Watson A; Nazir T; Carr SB; Wallis C; Marriott C; Hodson ME
Eur Respir J; 1997 Jun; 10(6):1261-6. PubMed ID: 9192926
[TBL] [Abstract][Full Text] [Related]
14. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis.
Suri R
BioDrugs; 2005; 19(3):135-44. PubMed ID: 15984899
[TBL] [Abstract][Full Text] [Related]
15. Respirable mass: vague and indefinable in disease.
Smaldone GC; Diot P; Groth M; Ilowite J
J Aerosol Med; 1998; 11 Suppl 1():S105-11. PubMed ID: 10180720
[No Abstract] [Full Text] [Related]
16. New treatment for cystic fibrosis.
Kuhn RJ
Am Pharm; 1994 Feb; NS34(2):16-8. PubMed ID: 8166040
[No Abstract] [Full Text] [Related]
17. The facilitating effect of hypertonic saline on resolution of airway inflammation in cystic fibrosis.
Reeves EP; McElvaney NG
Am J Respir Crit Care Med; 2012 Jan; 185(2):226-7. PubMed ID: 22351955
[No Abstract] [Full Text] [Related]
18. Cystic fibrosis pulmonary guidelines: airway clearance therapies.
Flume PA; Robinson KA; O'Sullivan BP; Finder JD; Vender RL; Willey-Courand DB; White TB; Marshall BC;
Respir Care; 2009 Apr; 54(4):522-37. PubMed ID: 19327189
[TBL] [Abstract][Full Text] [Related]
19. Expiratory ventilatory capacity measurements in children with cystic fibrosis treated by oral acetylcysteine.
Steil E; Niessen KH
Eur J Respir Dis Suppl; 1980; 111():132-3. PubMed ID: 6938398
[No Abstract] [Full Text] [Related]
20. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
